下肢不同部位深静脉血栓抗凝疗程的研究新进展

doi:10.12114/j.issn.1007-9572.2024.0472

中国全科医学 ›› 2025, Vol. 28 ›› Issue (29): 3721-3728.DOI: 10.12114/j.issn.1007-9572.2024.0472

• 综述与专论 • 上一篇

下肢不同部位深静脉血栓抗凝疗程的研究新进展

马景滔¹, 黄劼²^,^*(), 张烨², 陈萌¹, 张智颖¹

1．314001　浙江省嘉兴市，浙江中医药大学
2．314001　浙江省嘉兴市，嘉兴大学附属医院　嘉兴市第一医院全科医学科

收稿日期:2024-08-10 修回日期:2024-11-15 出版日期:2025-10-15 发布日期:2025-08-26
通讯作者: 黄劼
作者贡献：
马景滔进行文章的构思与设计，撰写论文；黄劼、张烨、陈萌进行文章的可行性分析；马景滔、陈萌、张智颖进行文献/资料收集；马景滔、张智颖进行文献/资料整理；马景滔、张烨进行论文的修订；黄劼、张烨负责文章的质量控制及审校；黄劼对文章整体负责，监督管理。
基金资助:
浙江省嘉兴市医学重点学科建设项目(2023-FC-002); 嘉兴市科技计划项目(2022AD30071); 嘉兴市第一医院科技计划项目(2023-YB-086)

Research Progress on Anticoagulant Therapy for Deep Vein Thrombosis in Different Parts of the Lower Extremity

MA Jingtao¹, HUANG Jie²^,^*(), ZHANG Ye², CHEN Meng¹, ZHANG Zhiying¹

1. Zhejiang Chinese Medical University, Jiaxing 314001, China
2. Department of General Practice, Affiliated Hospital of Jiaxing University/The First Hospital of Jiaxing, Jiaxing 314001, China

Received:2024-08-10 Revised:2024-11-15 Published:2025-10-15 Online:2025-08-26
Contact: HUANG Jie

摘要/Abstract

摘要： 下肢深静脉血栓形成（LEDVT）是常见的血管疾病之一，发病率逐年上升，目前对该疾病的治疗已有广泛研究，但疾病的个性化最优管理甚少。本文从下肢不同部位系统探讨了该疾病的血栓抗凝时间，并通过梳理相关文献，总结了目前小腿肌间静脉、小腿轴静脉、股腘静脉以及髂股静脉等不同部位抗凝疗程的循证建议。本文认为在下肢不同部位的深静脉血管中，远端深静脉血栓形成（DDVT）发生率高，而近端深静脉血栓形成（PDVT）并发肺栓塞（PE）和血栓形成后综合征（PTS）的概率更大。DDVT抗凝推荐采用短期抗凝（2~6周），延长抗凝疗程并不会带来更多的好处，相反还会增加出血风险；PDVT及混合型LEDVT应采用中长期抗凝（≥3个月），特别是未达到介入治疗指征的股腘深静脉血栓形成（FDVT）。无限期的抗凝治疗仅是延迟血栓栓塞的复发，并没有真正降低血栓复发风险。本文可为深入了解LEDVT和优化其抗凝疗程，以及为LEDVT的个性化抗凝治疗提供参考。

关键词: 下肢深静脉血栓形成, 抗凝疗程, 肺栓塞, 远端深静脉血栓形成, 近端深静脉血栓形成

Abstract:

Lower extremity deep vein thrombosis (LEDVT) is one of the common vascular diseases with its incidence increasing annually. Although extensive research has focused on treating LEDVT, personalized management strategies remain limited. This review systematically discussed the recommended duration of anticoagulant therapy for LEDVT in various locations of the lower extremities and summarized the evidence-based recommendations for the anticoagulation treatment of different parts of the calf intermuscular vein, calf axial vein, femoropopliteal vein, and iliofemoral vein. This review further emphasized that in different parts of the lower extremities, the incidence of distal deep vein thrombosis (DDVT) was high, while the probability of proximal deep vein thrombosis (PDVT) complicated with pulmonary embolism (PE) and post-thrombosis syndrome (PTS) was greater. Short-term anticoagulation (2-6 weeks) was recommended for DDVT. A prolonged anticoagulation course could not bring more benefits, whereas increased the risk of bleeding. PDVT and mixed LEDVT of lower extremities should be treated with medium and long-term anticoagulation (≥ 3 months), especially for femoropopliteal deep vein thrombosis (FDVT) that did not meet the indications of interventional treatment. Indefinite anticoagulation treatment only delayed the recurrence of thromboembolism, but did not really reduce the risk of thrombosis recurrence. The results of this review could provide reference for further understanding of LEDVT and optimization of anticoagulation course, as well as for personalized anticoagulation treatment of LEDVT.

Key words: Lower extremity deep vein thrombosis, Anticoagulation therapy, Pulmonary embolism, Distal deep vein thrombosis, Proximal deep vein thrombosis

中图分类号:

R 543

马景滔,黄劼,张烨,等. 下肢不同部位深静脉血栓抗凝疗程的研究新进展[J]. 中国全科医学, 2025, 28(29): 3721-3728. DOI: 10.12114/j.issn.1007-9572.2024.0472.
MA Jingtao,HUANG Jie,ZHANG Ye, et al. Research Progress on Anticoagulant Therapy for Deep Vein Thrombosis in Different Parts of the Lower Extremity[J]. Chinese General Practice, 2025, 28(29): 3721-3728. DOI: 10.12114/j.issn.1007-9572.2024.0472.

参考文献 59

[1]	KLEMEN N D, FEINGOLD P L, HASHIMOTO B，et al. Mortality risk associated with venous thromboembolism：a systematic review and Bayesian meta-analysis[J]. Lancet Haematol，2020,7(8):e583-593. DOI：10.1016/S2352-3026(20)30211-8.
[2]	LUTSEY P L, ZAKAI N A. Epidemiology and prevention of venous thromboembolism[J]. Nat Rev Cardiol，2023,20(4):248-262. DOI：10.1038/s41569-022-00787-6.
[3]	牛鹿原，张欢，张福先. 下肢静脉系统的解剖命名及超声学特征[J]. 中国血管外科杂志：电子版，2021,13(1):64-67. DOI：10.3969/j.issn.1674-7429.2021.01.015.
[4]	KUCZMIK W, WYSOKINSKI W E, HESLEY G K，et al. Calf vein thrombosis comparison of outcomes for axial and muscular venous thrombosis[J]. Thromb Haemost，2021,121(2):216-223. DOI：10.1055/s-0040-1715646.
[5]	WANG C J, SHI C, GUO R，et al. Comparison of clinical outcomes among patients with isolated axial vs muscular calf vein thrombosis：a systematic review and meta-analysis[J]. J Vasc Surg Venous Lymphat Disord，2024,12(2):101727. DOI：10.1016/j.jvsv.2023.101727.
[6]	DE MAESENEER M G, BOCHANEN N, VAN ROOIJEN G，et al. Analysis of 1，338 patients with acute lower limb deep venous thrombosis（DVT）supports the inadequacy of the term "proximal DVT" [J]. Eur J Vasc Endovasc Surg，2016,51(3):415-420. DOI：10.1016/j.ejvs.2015.11.001.
[7]	ROBERT-EBADI H, RIGHINI M. Management of distal deep vein thrombosis[J]. Thromb Res，2017,149:48-55. DOI：10.1016/j.thromres.2016.11.009.
[8]	STEVENS S M, WOLLER S C, KREUZIGER L B，et al. Antithrombotic therapy for VTE disease：second update of the CHEST guideline and expert panel report[J]. Chest，2021,160(6):e545-608. DOI：10.1016/j.chest.2021.07.055.
[9]	SCHELLONG S, AGENO W, CASELLA I B，et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism：re-COVERY DVT/PE study[J]. Semin Thromb Hemost，2022,48(4):446-458. DOI：10.1055/s-0041-1729169.
[10]	RO A, KAGEYAMA N, MUKAI T. Pathophysiology of venous thromboembolism with respect to the anatomical features of the deep veins of lower limbs：a review[J]. Ann Vasc Dis，2017,10(2):99-106. DOI：10.3400/avd.ra.17-00035.
[11]	RO A, KAGEYAMA N, TANIFUJI T，et al. Pulmonary thromboembolism：overview and update from medicolegal aspects[J]. Leg Med，2008,10(2):57-71. DOI：10.1016/j.legalmed.2007.09.003.
[12]	周爱强，范修锦，邱涛，等. 小腿肌间静脉血栓诊治的争议与进展[J]. 中国血管外科杂志（电子版），2022,14(4):367-371,384. DOI：10.3969/j.issn.1674-7429.2022.04.020.
[13]	李晓强，张福先，王深明. 深静脉血栓形成的诊断和治疗指南（第三版）[J]. 中国血管外科杂志（电子版），2017,9(4):250-257.
[14]	牛文强，李鲁滨，车海杰，等. 小腿肌肉静脉血栓的诊疗进展[J]. 中国临床医生杂志，2022,50(4):411-413. DOI：10.3969/j.issn.2095-8552.2022.04.011.
[15]	SCHWARZ T, BUSCHMANN L, BEYER J，et al. Therapy of isolated calf muscle vein thrombosis：a randomized，controlled study[J]. J Vasc Surg，2010,52(5):1246-1250.
[16]	SALES C M, HAQ F, BUSTAMI R，et al. Management of isolated soleal and gastrocnemius vein thrombosis[J]. J Vasc Surg，2010,52(5):1251-1254. DOI：10.1016/j.jvs.2010.05.102.
[17]	MERRIMAN E, CHUNILAL S, BRIGHTON T，et al. Two weeks of low molecular weight heparin for isolated symptomatic distal vein thrombosis（TWISTER study）[J]. Thromb Res，2021,207:33-39. DOI：10.1016/j.thromres.2021.09.004.
[18]	中国微循环学会周围血管疾病专业委员会. 远端深静脉血栓形成诊疗微循环专家共识[J]. 血管与腔内血管外科杂志，2021,7(8):890-903,908. DOI：10.19418/j.cnki.issn2096-0646.2021.08.02.
[19]	郭媛媛，李敏，郭丰勇，等. 急性孤立性小腿肌间静脉血栓不同抗凝治疗时限的中、短期疗效观察[J]. 中国普通外科杂志，2013,22(12):1605-1608. DOI：10.7659/j.issn.1005-6947.2013.12.016.
[20]	RIGHINI M, GALANAUD J P, GUENNEGUEZ H，et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis（CACTUS）：a randomised，double-blind，placebo-controlled trial[J]. Lancet Haematol，2016,3(12):e556-562. DOI：10.1016/S2352-3026(16)30131-4.
[21]	KRET M R, LIEM T K, MITCHELL E L，et al. Isolated calf muscular vein thrombosis is associated with pulmonary embolism and a high incidence of additional ipsilateral and contralateral deep venous thrombosis[J]. J Vasc Surg Venous Lymphat Disord，2013,1(1):33-38. DOI：10.1016/j.jvsv.2012.04.001.
[22]	马玉林，单位，杨昱. 孤立性远端深静脉血栓的抗凝疗程分析[J]. 中国医科大学学报，2023,52(4):379-381. DOI：10.12007/j.issn.0258-4646.2023.04.018.
[23]	MASUDA E M, KISTNER R L, MUSIKASINTHORN C，et al. The controversy of managing calf vein thrombosis[J]. J Vasc Surg，2012,55(2):550-561. DOI：10.1016/j.jvs.2011.05.092.
[24]	GALANAUD J P, SEVESTRE M A, GENTY C，et al. Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis[J]. J Vasc Surg，2010,52(4):932-938,938.e1-938.e2.
[25]	SARTORI M, MIGLIACCIO L, FAVARETTO E，et al. Two years outcome of isolated distal deep vein thrombosis[J]. Thromb Res，2014,134(1):36-40. DOI：10.1016/j.thromres.2014.03.033.
[26]	LI A Y, WOULFE T, ROLFE-VYSON V，et al. Management and outcomes of axial isolated distal deep vein thrombosis at north shore hospital，New Zealand：a retrospective audit[J]. Intern Med J，2015,45(2):177-182. DOI：10.1111/imj.12664.
[27]	SINGH K, YAKOUB D, GIANGOLA P，et al. Early follow-up and treatment recommendations for isolated calf deep venous thrombosis[J]. J Vasc Surg，2012,55(1):136-140.
[28]	SARTORI M, LESSIANI G, FAVARETTO E，et al. Ultrasound characteristics of calf deep vein thrombosis and residual vein obstruction after low molecular weight heparin treatment[J]. Eur J Vasc Endovasc Surg，2016,52(5):658-664.
[29]	中国医师协会血管外科医师分会静脉学组. 常见静脉疾病诊治规范（2022年版）[J]. 中华普通外科学文献：电子版，2022,16(4):255-272. DOI：10.3877/cma.j.issn.1674-0793.2022.04.002.
[30]	刘宝坤，周栋，屈睿升，等. 急性下肢深静脉血栓的腔内治疗进展[J]. 临床放射学杂志，2022,41(3):571-574.
[31]	GARCIA R, LABROPOULOS N, GASPARIS A P，et al. Present and future options for treatment of infrainguinal deep vein disease[J]. J Vasc Surg Venous Lymphat Disord，2018,6(5):664-671. DOI：10.1016/j.jvsv.2018.01.010.
[32]	BROHOLM R, BÆKGAARD N, HANSEN S，et al. Significance of partial or complete thrombosis of the common and deep femoral vein in patients with deep vein thrombosis[J]. Eur J Vasc Endovasc Surg，2019,58(4):570-575. DOI：10.1016/j.ejvs.2019.06.016.
[33]	殷敏毅，叶开创. 急性下肢深静脉血栓形成腔内治疗专家共识[J]. 血管与腔内血管外科杂志，2023,9(5):513-519. DOI：10.19418/j.cnki.issn2096-0646.2023.05.01.
[34]	佟冰渡，高娜，王晓杰，等. 近端下肢深静脉血栓患者预后现状及影响因素分析[J]. 中国护理管理，2018,18(8):1120-1125. DOI：10.3969/j.issn.1672-1756.2020.04.020.
[35]	KLEIN S J, GASPARIS A P, VIRVILIS D，et al. Prospective determination of candidates for thrombolysis in patients with acute proximal deep vein thrombosis[J]. J Vasc Surg，2010,51(4):908-912. DOI：10.1016/j.jvs.2009.11.043.
[36]	李梦婷，潘峰，李林杨炼，等. 急性髂股静脉血栓的介入治疗研究进展[J]. 临床放射学杂志，2024,43(3):467-471.
[37]	LIU G, ZHAO Z, CUI C Y，et al. Endovascular management of extensive lower extremity acute deep vein thrombosis with AngioJet rheolytic thrombectomy plus catheter-directed thrombolysis from contralateral femoral access[J]. Phlebology，2019,34(4):257-265. DOI：10.1177/0268355518790407.
[38]	KEARON C, GU C S, JULIAN J A，et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis：analysis from a stratified randomized trial[J]. Thromb Haemost，2019,119(4):633-644.
[39]	MAGNUSON E A, CHINNAKONDEPALLI K, VILAIN K，et al. Cost-effectiveness of pharmacomechanical catheter-directed thrombolysis versus standard anticoagulation in patients with proximal deep vein thrombosis：results from the ATTRACT trial[J]. Circ Cardiovasc Qual Outcomes，2019,12(10):e005659. DOI：10.1161/CIRCOUTCOMES.119.005659.
[40]	LIN M Y, HSIEH J C F, HANIF M，et al. Evaluation of thrombolysis using tissue plasminogen activator in lower extremity deep venous thrombosis with concomitant femoral-popliteal venous segment involvement[J]. J Vasc Surg Venous Lymphat Disord，2017,5(5):613-620. DOI：10.1016/j.jvsv.2017.04.018.
[41]	DOUKETIS J D, CROWTHER M A, FOSTER G A，et al. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?[J]. Am J Med，2001,110(7):515-519. DOI：10.1016/s0002-9343(01)00661-1.
[42]	COUTURAUD F, PERNOD G, PRESLES E，et al. Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial[J]. Haematologica，2019,104(7):1493-1501. DOI：10.3324/haematol.2018.210971.
[43]	AGNELLI G, PRANDONI P, SANTAMARIA M G，et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators[J]. N Engl J Med，2001,345(3):165-169. DOI：10.1056/NEJM200107193450302.
[44]	顾建平，徐克，滕皋军. 下肢深静脉血栓形成介入治疗规范的专家共识（第2版）[J]. 介入放射学杂志，2019,28(1):1-10. DOI：10.3969/j.issn.1008-794X.2019.01.001.
[45]	KAHN S R, COMEROTA A J, CUSHMAN M，et al. The postthrombotic syndrome：evidence-based prevention，diagnosis，and treatment strategies：a scientific statement from the American Heart Association[J]. Circulation，2014,130(18):1636-1661. DOI：10.1161/CIR.0000000000000130.
[46]	ENDEN T, HAIG Y, KLØW N E，et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis（the CaVenT study）：a randomised controlled trial[J]. Lancet，2012,379(9810):31-38. DOI：10.1016/S0140-6736(11)61753-4.
[47]	KAKKOS S K, GOHEL M, BAEKGAARD N，et al. Editor's choice - European society for vascular surgery（ESVS）2021 clinical practice guidelines on the management of venous thrombosis[J]. Eur J Vasc Endovasc Surg，2021,61(1):9-82.
[48]	ABRAMOWITZ S, SHAIKH A, MOJIBIAN H，et al. Comparison of anticoagulation vs mechanical thrombectomy for the treatment of iliofemoral deep vein thrombosis[J]. J Vasc Surg Venous Lymphat Disord，2024,12(4):101825. DOI：10.1016/j.jvsv.2024.101825.
[49]	TSAI C J, LEE C Y. Comparative outcomes of catheter-directed thrombolysis plus rivaroxaban vs rivaroxaban alone in patients with acute iliofemoral deep vein thrombosis[J]. J Chin Med Assoc，2019,82(12):902-908.
[50]	BRADBURY C, FLETCHER K, SUN Y Z，et al. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism（VTE）and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE（the ExACT study）[J]. Br J Haematol，2020,188(6):962-975. DOI：10.1111/bjh.16275.
[51]	SCHULMAN S, LINDMARKER P, HOLMSTRÖM M，et al. Post-thrombotic syndrome，recurrence，and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months[J]. J Thromb Haemost，2006,4(4):734-742.
[52]	GALANAUD J P, SEVESTRE M A, GENTY C，et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis[J]. J Thromb Haemost，2014,12(4):436-443. DOI：10.1111/jth.12512.
[53]	ASONITIS K, CHARVALOS E, LAMBERT C，et al. Experience of a 40-day（6 week）LMWH treatment for isolated distal deep vein thrombosis[J]. J Thromb Thrombolysis，2020,50(4):837-843. DOI：10.1007/s11239-020-02089-5.
[54]	FERRARA F, MELI F, AMATO C，et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins[J]. Angiology，2006,57(4):418-423.
[55]	HAIG Y, ENDEN T, GRØTTA O，et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis（CaVenT）：5-year follow-up results of an open-label，randomised controlled trial[J]. Lancet Haematol，2016,3(2):e64-71. DOI：10.1016/S2352-3026(15)00248-3.
[56]	张明照，卢冉，向军益，等. 经皮穿刺胫后静脉入路治疗急性混合型单侧下肢深静脉血栓形成的疗效[J]. 中华全科医学，2022,20(4):560-564.
[57]	AGNELLI G, BULLER H R, COHEN A，et al. Oral apixaban for the treatment of acute venous thromboembolism[J]. N Engl J Med，2013,369(9):799-808.
[58]	CASTELLUCCI L A, CAMERON C, GAL G L，et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism：a systematic review and meta-analysis[J]. JAMA，2014,312(11):1122-1135.
[59]	INVESTIGATORS H V, BÜLLER H R, DÉCOUSUS H，et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J]. N Engl J Med，2013,369(15):1406-1415. DOI：10.1056/NEJMoa1306638.

下肢不同部位深静脉血栓抗凝疗程的研究新进展

Research Progress on Anticoagulant Therapy for Deep Vein Thrombosis in Different Parts of the Lower Extremity

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 59

相关文章 15

编辑推荐

Metrics

留言

[1]	米凌玉, 陈连鑫, 高恒波, 王彬成. 三酰甘油-葡萄糖指数对肺栓塞患者预后的预测价值研究[J]. 中国全科医学, 2025, 28(35): 4421-4429.
[2]	杨佳诺, 王冠理, 杨佳夫, 何嘉豪, 陈舒敏, 沈毅, 李娟, 任妮, 刘春丽, 邓方阁. 红外热成像在肺部疾病应用的新进展[J]. 中国全科医学, 2025, 28(08): 1012-1016.
[3]	吕广瑜, 孙宛君, 周倩倩, 陈先梦, 刘雪晗, 胡晓文. 误诊为肺炎的中高危肺栓塞继发肺梗死患者临床特征及相关危险因素研究[J]. 中国全科医学, 2024, 27(32): 3987-3992.
[4]	王武超, 刘思齐, 刘倩倩, 朱继红. 急性肺栓塞合并血小板减少患者临床特点的回顾性研究[J]. 中国全科医学, 2024, 27(27): 3372-3377.
[5]	曾令聪, 张龙举, 周玲, 张伟, 代梦, 黄银, 黄毅. 4级肺栓塞临床概率评分对老年急性肺栓塞的预测价值研究[J]. 中国全科医学, 2024, 27(09): 1062-1067.
[6]	王翠娅, 张军娜, 臧会铃, 吕畅, 郭慧, 马志超, 李建国. 腹痛病因清单在血管性疾病鉴别诊断中的应用——附三例病例分析[J]. 中国全科医学, 2022, 25(36): 4577-4581.
[7]	王悦悦，许启霞. 可疑肺栓塞诊断新策略——YEARS评分[J]. 中国全科医学, 2021, 24(26): 3383-3386.
[8]	孙峰，燕存子，夏宇，王在义*. 不伴红细胞增多的慢性阻塞性肺疾病患者并发肺栓塞的影响因素研究[J]. 中国全科医学, 2020, 23(24): 3018-3022.
[9]	解银立，张大春，支兴兴，朱锐，翁高洁，周峰，杨丽，徐虔，周石. 可取回型下腔静脉滤器预防下肢骨折合并深静脉血栓形成患者围术期肺动脉栓塞的价值研究[J]. 中国全科医学, 2019, 22(6): 715-719.
[10]	徐琪1，周瑞清2，王红旗3，孙良4，万俊峰4. 老年肺栓塞早期诊断延误的影响因素研究[J]. 中国全科医学, 2018, 21(7): 804-808.
[11]	施宇衡，陈艳艳，马佳韵. 门诊初诊的急性肺栓塞患者诊断延误情况及临床特征分析[J]. 中国全科医学, 2018, 21(31): 3832-3836.
[12]	蔺莉，王静. 重视高危因素，规范管理、合理诊治妊娠期血栓栓塞性疾病——《2018 ACOG实践简报：妊娠期血栓栓塞症的临床管理指南》解读[J]. 中国全科医学, 2018, 21(30): 3659-3664.
[13]	杜昌，余剑波，朱继红. 存在溶栓禁忌证的肺血栓栓塞症患者治疗策略分析[J]. 中国全科医学, 2018, 21(2): 194-198.
[14]	万静萱，李红红，杨叶梦，马琳. 血浆D-二聚体诊断肺癌合并肺栓塞的最佳临界值研究[J]. 中国全科医学, 2018, 21(10): 1212-1215.
[15]	汪雁博，蒋杏杏，范卫泽，谷新顺*. 成年人法洛四联症合并大面积肺栓塞一例报道并文献复习[J]. 中国全科医学, 2017, 20(8): 1002-1004.